TY - JOUR
T1 - Omani experience with the use of factor IX Fc fusion protein
AU - Alzadjali, Shireen I.
AU - Wali, Yasser
N1 - Publisher Copyright:
©
PY - 2021/7/21
Y1 - 2021/7/21
N2 - We describe our local experience in the management of haemophilia B patients with factor IX Fc fusion protein. Two children with haemophilia B were managed with the use of a personalised/tailored dosing schedule of factor IX Fc fusion protein. Compared with the standard half-life factor IX, prophylaxis with factor IX Fc fusion protein was cost-effective, with much less injections, better bleeding control, improved tolerability or no inhibitor development.
AB - We describe our local experience in the management of haemophilia B patients with factor IX Fc fusion protein. Two children with haemophilia B were managed with the use of a personalised/tailored dosing schedule of factor IX Fc fusion protein. Compared with the standard half-life factor IX, prophylaxis with factor IX Fc fusion protein was cost-effective, with much less injections, better bleeding control, improved tolerability or no inhibitor development.
KW - congenital disorders
KW - haematology (incl blood transfusion)
KW - paediatrics
UR - http://www.scopus.com/inward/record.url?scp=85111116293&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111116293&partnerID=8YFLogxK
U2 - 10.1136/bcr-2020-241154
DO - 10.1136/bcr-2020-241154
M3 - Article
C2 - 34290003
AN - SCOPUS:85111116293
SN - 1757-790X
VL - 14
JO - BMJ Case Reports
JF - BMJ Case Reports
IS - 7
M1 - e241154
ER -